Genetic manipulation or pharmacological methods have demonstrated that blocking HSP90β can greatly improve obesity-related fatty liver disease, type 2 diabetes, and atherosclerosis by suppressing SREBP function. Here, HSP90AB1 is linked to obesity due to melanocortin 4 receptor deficiency.